Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
61
MRKR Quote, Financials, Valuation and Earnings
Last price:
$2.02
Seasonality move
:
11.17%
Day range:
$1.93 - $2.29
52-week range:
$0.81 - $4.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.53x
P/B ratio:
1.85x
Volume:
869.8K
Avg. volume:
471.7K
1-year change:
-5.56%
Market cap:
$34M
Revenue:
$6.6M
EPS (TTM):
-$1.23
Analysts' Opinion
-
Consensus RatingMarker Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.87, Marker Therapeutics, Inc. has an estimated upside of 285.62% from its current price of $2.04.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.60 representing 100% downside risk from its current price of $2.04.
Fair Value
-
According to the consensus of 3 analysts, Marker Therapeutics, Inc. has 285.62% upside to fair value with a price target of $7.87 per share.
MRKR vs. S&P 500
-
Over the past 5 trading days, Marker Therapeutics, Inc. has overperformed the S&P 500 by 12.52% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Marker Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Marker Therapeutics, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Marker Therapeutics, Inc. reported revenues of $1.2M.
Earnings Growth
-
Marker Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Marker Therapeutics, Inc. reported earnings per share of -$0.12.
Enterprise value:
15.1M
EV / Invested capital:
--
Price / LTM sales:
5.53x
EV / EBIT:
--
EV / Revenue:
3.21x
PEG ratio (5yr expected):
-0.12x
EV / Free cash flow:
-1.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-82.72%
Net Income Margin (TTM):
-304.54%
Return On Equity:
-103.04%
Return On Invested Capital:
-103.04%
Operating Margin:
-173.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3M | $5.4M | $4.7M | $1.9M | $1.2M | |
| Gross Profit | $6.1M | -- | -- | -- | -- | |
| Operating Income | -$13.8M | -$10.2M | -$14.9M | -$2.4M | -$2.1M | |
| EBITDA | -$13.8M | -$10.2M | -$14.4M | -$2.4M | -$2.1M | |
| Diluted EPS | -$2.08 | -$1.08 | -$1.23 | -$0.26 | -$0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $51.4M | $22.4M | $19.5M | $10.9M | $21.7M | |
| Total Assets | $71.9M | $41.1M | $19.5M | $10.9M | $21.7M | |
| Current Liabilities | $8.2M | $11.3M | $2.8M | $3.5M | $3.3M | |
| Total Liabilities | $19.7M | $18.5M | $2.8M | $3.5M | $3.3M | |
| Total Equity | $52.3M | $22.6M | $16.7M | $7.4M | $18.4M | |
| Total Debt | $11.4M | $7.2M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.4M | -$8.6M | -$14.8M | $1.2M | -$2.7M | |
| Cash From Investing | $18.5M | -- | -- | -- | -- | |
| Cash From Financing | $1.2M | $100.5K | $24.8M | $1.7K | $9.9M | |
| Free Cash Flow | -$20.4M | -$8.6M | -$14.8M | $1.2M | -$2.7M | |
MRKR
Sector
Market Cap
$34M
$26M
Price % of 52-Week High
50.12%
51.81%
Dividend Yield
0%
0%
Shareholder Yield
-166.37%
-1.66%
1-Year Price Total Return
-5.56%
-18.29%
Beta (5-Year)
1.371
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.91
200-day SMA
Buy
Level
$1.26
Bollinger Bands (100)
Buy
Level
0.83 - 1.53
Chaikin Money Flow
Sell
Level
-100.6M
20-day SMA
Buy
Level
$1.76
Relative Strength Index (RSI14)
Buy
Level
61.54
ADX Line
Buy
Level
43.49
Williams %R
Neutral
Level
-43.75
50-day SMA
Buy
Level
$1.40
MACD (12, 26)
Buy
Level
0.18
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
81.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-23.0046)
Sell
CA Score
(Annual)
Level (-1.3651)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.0583)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Stock Forecast FAQ
In the current month, MRKR has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRKR average analyst price target in the past 3 months is $7.87.
-
Where Will Marker Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Marker Therapeutics, Inc. share price will rise to $7.87 per share over the next 12 months.
-
What Do Analysts Say About Marker Therapeutics, Inc.?
Analysts are divided on their view about Marker Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Marker Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $5.60.
-
What Is Marker Therapeutics, Inc.'s Price Target?
The price target for Marker Therapeutics, Inc. over the next 1-year time period is forecast to be $7.87 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MRKR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Marker Therapeutics, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MRKR?
You can purchase shares of Marker Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Marker Therapeutics, Inc. shares.
-
What Is The Marker Therapeutics, Inc. Share Price Today?
Marker Therapeutics, Inc. was last trading at $2.02 per share. This represents the most recent stock quote for Marker Therapeutics, Inc.. Yesterday, Marker Therapeutics, Inc. closed at $2.04 per share.
-
How To Buy Marker Therapeutics, Inc. Stock Online?
In order to purchase Marker Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MRKR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MRKR
Sector
P/E ratio
--
23.85x
PEG ratio
-0.12x
-0.01x
P/B ratio
1.85x
1.83x
Price / LTM sales
5.53x
1.56x
Growth Metrics
MRKR
Sector
Revenue growth
-35.99%
4.18%
Earnings growth
53.89%
9.66%
Revenue (5-year growth)
98.63%
6.28%
Earnings forecast
-$0.19
-$0.18
Profitability
MRKR
Sector
Profitability FY 2024
--
$3.1M
Return on invested capital
-103.04%
-32.89%
Return on assets
-82.72%
-29.56%
Return on equity
-103.04%
-38.66%
Earnings Date
Last Earnings Date
Jan
23
Next Earnings Date
Jan
23
Estimated Next Earnings Date
Apr
24
Balance Sheet
MRKR
Sector
Total cash
$18.9M
$25.2M
Short term investments
--
$25.1M
Total assets
$22M
$73M
Long term debt
--
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is up 7.31% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 9.62% over the past day.
Sell
24
INSP alert for Jan 23
Inspire Medical Systems, Inc. [INSP] is down 1.14% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
